Author: admin

Battery Coating Market Size, Regional Outlook, Valuable Growth Factors, Business Strategies and Future Demand 2030

“Browse 246 market data Tables and 60 Figures spread through 257 Pages and in-depth TOC on “Battery Coating Market””
The battery coating market is driven by rising demand for efficient, durable batteries across industries like EVs and electronics. Advancements in coating technologies improve performance, safety, and longevity. With sustainability trends, the market is poised for significant growth globally.

The global battery coating market is anticipated to grow from USD 604.7 million in 2024 to USD 1,613.6 million in 2030, at a CAGR of 17.8% during the forecast period. The surge in the battery coating market is driven by the increasing demand for high-performance and durable batteries, especially in the electric vehicle (EV) industry. As EV adoption rises globally, the need for efficient and longer-lasting batteries becomes more critical. Battery coatings play a vital role in enhancing the performance of lithium-ion batteries, which are widely used in EVs. These coatings improve battery lifespan by reducing degradation, enhancing thermal stability, and protecting against chemical reactions within the cells, contributing to the development of longer-range EVs and faster charging solutions.

By battery type, the graphene battery segment is estimated to be the fastest-growing battery coating type segment from 2024 to 2030.

Graphene batteries have the highest compound annual growth rate (CAGR) among battery types due to their potential to outperform conventional batteries in terms of energy density, charging speed, and durability. Graphene’s unique properties, such as high electrical conductivity, excellent mechanical strength, and lightweight structure, enable it to enhance battery performance significantly. These batteries can store more energy, charge faster, and maintain stable performance over more charge cycles, making them ideal for applications like electric vehicles (EVs) and consumer electronics.

Download PDF brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=24757097

In electric vehicles, where battery efficiency and range are critical, graphene batteries offer the potential for longer driving ranges and reduced charging times, key factors driving their rapid adoption. Furthermore, graphene’s thermal conductivity helps prevent overheating, increasing battery safety. The ongoing advancements in graphene battery technology, along with rising investments in research and development, are propelling the growth of this segment. These benefits position graphene batteries as a promising alternative to traditional lithium-ion batteries, driving their high CAGR.

By material, the PVDF segment type will be the largest in the battery coating market 2023.

The PVDF (Polyvinylidene fluoride) segment is the largest in the battery coating market because of its exceptional chemical and thermal stability, strong adhesion properties, and high solvent resistance. PVDF is widely used as a binder and coating material for lithium-ion battery electrodes, particularly in electric vehicles (EVs) and energy storage systems. Its ability to enhance battery components’ durability, conductivity, and mechanical strength makes it an essential material in battery coatings.

In lithium-ion batteries, PVDF coatings help improve the efficiency and lifespan of the battery by reducing degradation during charge and discharge cycles, improving thermal management, and maintaining stability under harsh operating conditions. As the demand for longer-lasting, safer, and more efficient batteries increases, particularly in the rapidly growing EV market, the use of PVDF in battery coatings continues to expand.

Asia Pacific is estimated to be the largest region in the battery coating market in 2023.

The battery coating market has the largest market share in Asia Pacific in 2023. This is because the region is home to various automotive electric vehicle giants. China, in particular, has emerged as a significant player in the EV market, with companies like BYD and SAIC-GM-Wuling producing a wide range of electric vehicles. Other countries in the region, such as Japan, South Korea, and India, are also making significant strides in EV development and adoption. Many companies like Google, Facebook, and Amazon operate in this region. The government policies also push them to minimize their carbon footprint. This region has some vast companies like Mitsubishi Paper Mills Ltd. (Japan), Ube Industries Ltd. (Japan), Tanaka Chemical Corporation (Japan), Asahi Kasei Corporation (Japan), and SK Innovation Co., Ltd. (South Korea) and others, which further solidifies its position in the market.

Battery Coating Companies

Companies such as Arkema (France), Solvay (Belgium), Asahi Kasei Corporation (Japan), UBE Corporation (Japan), and PPG Industries, Inc. (US) fall into the winners’ category. These are leading players in the global market. These players have adopted including expansions, agreements, product launches, and partnerships.

ARKEMA (FRANCE)Arkema manufactures and supplies chemical products. It operates through Adhesive Solutions, Advanced Materials, Coating Solutions, Intermediates, and corporate segments. The Advanced Materials segment produces specialty polyamides, PVDF, organic peroxides, thiochemicals, hydrogen peroxide, surfactants & additives, molecular sieves & FEBEX, and UV curing resins (Sartomer), which are used in varied sectors such as transportation, oil extraction, renewable energy, consumer goods, electronics, construction, coatings, and water treatment.

Get a Sample Copy of This Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=24757097

The Coating Solutions segment sells and manufactures acrylic monomers, coating resins, and photocurable resins. The Intermediates segment manufactures fluoro gases. The Advanced Materials segment sells and manufactures coating materials for batteries. The company marks its global presence by providing its products and solutions through its 151 production plants across 55 countries.

SOLVAY(BELGIUM)Solvay manufactures and distributes chemical and plastic products. It is one of the leading chemical and plastic manufacturers worldwide. The company offers a wide range of products, including soda ash, hydrogen peroxide, functional polymers, silica, surfactants, food and fragrance flavors, and other specialty polymers for applications in aerospace, alternative energy, automotive, chemical, construction, consumer goods, food & beverage, and oil & gas industries. The company also offers a range of customized products in the advanced materials and specialty chemicals sectors. Solvay manages its business through Basic Chemicals, Performance Chemicals, and Corporate & Business Services. It has a wide geographical presence across Europe and North America.

ASAHI KASEI CORPORATION(JAPAN)Asahi Kasei Corporation is a global Japanese chemical company. It is one of the leading manufacturers of lithium-ion batteries and lead-acid battery separators, delivering high-quality, innovative, and sustainable solutions in the battery market. The company has four business segments: Material, Homes, Health Care, and Others. Under the Material segment, it provides various products and solutions, including environmental solutions, mobility and industrial solutions, and life innovation solutions.

The company provides pharmaceuticals, medical care solutions, and acute critical care through its healthcare segment. It also provides construction materials for the home business segment. The company marks its global presence by providing its products and solutions across Japan, the US, China, and other regions.

PPG INDUSTRIES, INC. (US)PPG Industries, Inc. manufactures and distributes paints, coatings, and specialty materials. It supplies coatings and specialty materials for various end uses, including industrial equipment and components, packaging material, aircraft and marine equipment, automotive original equipment, automotive refinish, pavement marking products, and coatings for other industrial and consumer products.

The company operates through the Performance Coatings and Industrial Coatings segments. The Performance Coatings business segment comprises automotive refinish coatings, aerospace coatings, architectural coatings, protective and marine coatings, and traffic solutions operating subsegments. The Industrial Coatings reportable segment comprises automotive OEM coatings, industrial coatings, packaging coatings, specialty coatings, and materials operating subsegments. The Industrial Coatings segment deals with manufacturing and selling battery coating materials.

Inquire Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=24757097

The company offers a range of EV battery module and pack solutions that provide dielectric protection, fire protection, thermal management, sealing, bonding, corrosion & impact protection, and EMI/RFI shielding. PPG Industries, Inc. is a global leader, serving sectors such as construction, consumer products, industrial, and transportation markets and aftermarkets. The company has manufacturing facilities and equity affiliates in more than 70 countries in Brussels, Belgium; Bollate, Italy; Aubervilliers, France; Changshu, China; and Alpharetta, Georgia.

UBE CORPORATION(JAPAN)UBE Corporation was established after merging various companies operating under the Anonymous Union Okinoyama Coal Mine Association. These companies had expertise in machinery, cement, and chemicals. However, UBE Corporation has expanded its business and operates under various segments, including Specialty Products, Polymers and chemicals, Machinery, and Others.

The company provides battery coating for the specialty products business segment. UBE Corporation offers a wide range of products that can be summarized as elastomers, engineering plastics, UBE caprolactam, industrial chemicals, liquified gas, separation membranes, ceramics, semiconductor gas products, and pharmaceutical products. The company marks its global presence by providing its products and solutions across Asia Pacific and Europe.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/battery-coating-market-24757097.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Battery Coating Market Size, Regional Outlook, Valuable Growth Factors, Business Strategies and Future Demand 2030

Hemophilia B Pipeline 2024: Detailed Clinical Trials and FDA-Approved Therapies Review by DelveInsight | Novo Nordisk, Sanofi, Pfizer, Belief BioMed, Centessa Pharmaceuticals

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Hemophilia B pipeline constitutes 15+ key companies continuously working towards developing 20+ Hemophilia B treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

“Hemophilia B Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hemophilia B Market.

 

The Hemophilia B Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Hemophilia B Pipeline Report

  • Companies across the globe are diligently working toward developing novel Hemophilia B treatment therapies with a considerable amount of success over the years. Hemophilia B Key players such as – Belief Biomed, ISU ABXIS, TiumBio, Be Biopharma, Regeneron Pharmaceuticals, Pfizer, Biocad, CSL Behring, Shanghai Vitalgen BioPharma, Baxalta, Amarna therapeutics, Catalyst Biosciences, Freeline Therapeutics, Belief BioMed, Centessa Pharmaceuticals, Novo Nordisk, Sanofi, Pfizer, and others are developing therapies for the Hemophilia B treatment

  • Hemophilia B Emerging therapies such as – BBM-H901, ISU304, TU7710, BE-101, REGV131, PF-06838435, ANB-002, AAV5-hFIXco-Padua, VGB-R04, AskBio009, AMA005, CB 2679d-GT, FLT180a, BBM-H901, SerpinPC, Concizumab, Fitusiran, PF-06, and others are expected to have a significant impact on the Hemophilia B market in the coming years.

  • In December 2024, Be Biopharma has initiated the first-in-human Phase 1/2 clinical trial of BE-101, its innovative B-cell therapy for hemophilia B, with patient enrollment underway at two U.S. sites. BE-101, a first-of-its-kind treatment, seeks to address ongoing challenges faced by hemophilia B patients, including the burden of regular treatment and disease management, as many still experience frequent bleeding episodes. The two-part Phase 1/2 trial, named BeCoMe-9 (NCT06611436), is designed to evaluate the safety and clinical activity of a single intravenous infusion of BE-101 in adults with moderately severe to severe hemophilia B.

  • In July 2024, CSL Behring has reported the treatment of two patients with HEMGENIX (etranacogene dezaparvovec) gene therapy for haemophilia B, a hereditary bleeding condition. The treatments were administered at haemophilia centres in France. HEMGENIX underwent extensive clinical development led by UniQure, with CSL Behring assuming sponsorship of the trials after acquiring global commercial rights to the therapy.

 

Hemophilia B Overview

Hemophilia B is a rare genetic bleeding disorder in which affected individuals have insufficient blood protein levels called factor IX. Hemophilia B, also known as factor IX deficiency or Christmas disease, is the second most common type of hemophilia. Factor IX is a clotting factor. Clotting factors are specialized proteins needed for blood clotting, the process by which blood seals a wound to stop bleeding and promote healing. Individuals with hemophilia B do not bleed faster than unaffected individuals, they bleed longer.

 

To know more about the Hemophilia B pipeline report, click here:

https://www.delveinsight.com/report-store/hemophilia-b-pipeline-insight

 

Hemophilia B Pipeline Therapies along with Key Players:

  • BBM-H901: Belief Biomed

  • ISU304: ISU ABXIS

  • TU7710: TiumBio

  • BE-101: Be Biopharma

  • REGV131: Regeneron Pharmaceuticals

  • PF-06838435: Pfizer

  • ANB-002: Biocad

  • AAV5-hFIXco-Padua: CSL Behring

  • VGB-R04: Shanghai Vitalgen BioPharma

  • AskBio009: Baxalta

  • AMA005: Amarna therapeutics

  • CB 2679d-GT: Catalyst Biosciences

  • FLT180a: Freeline Therapeutics

  • BBM-H901: Belief BioMed

  • SerpinPC: Centessa Pharmaceuticals

  • Concizumab: Novo Nordisk

  • Fitusiran: Sanofi

  • PF-06741086: Pfizer

 

Hemophilia B Pipeline Therapeutics Assessment

TheHemophilia B Pipeline report proffers an integral view of the Hemophilia B emerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action, and Route of Administration.

 

Hemophilia B Pipeline Clinical Phases:

DelveInsight’s Report covers around 20+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) along with the details of

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

 

Further Hemophilia B product details are provided in the report. Download the Hemophilia B pipeline report to learn more about the emerging Hemophilia B therapies

 

Some of the key companies in the Hemophilia B Therapeutics Market include:

Key companies developing therapies for Hemophilia B treatment are – Aptevo, Bayer, BioMarin, Catalyst Biosciences, CSL Behring, GC Pharma, Kaifeng Pharmaceutical, KM Biologics, LFB, Novo Nordisk, Pfizer, Octapharma, Roche, Sanofi, SinoCelltech, Spark Therapeutics, Takeda, UniQure, and others.

 

 

Hemophilia B Pipeline Analysis:

The report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the Hemophilia B treatment with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hemophilia B Treatment.

  • Hemophilia B key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Hemophilia B Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hemophilia B market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Hemophilia B Pipeline Market Drivers

  • Increasing prevalence of Hemophilia B disease

  • Increasing R&D on identifying new therapeutic agents

 

Hemophilia B Pipeline Market Barriers

  • High cost of Hemophilia B treatment

 

Scope of Hemophilia B Pipeline Drug Insight

  • Coverage: Global

  • Key Hemophilia B Companies: Belief Biomed, ISU ABXIS, TiumBio, Be Biopharma, Regeneron Pharmaceuticals, Pfizer, Biocad, CSL Behring, Shanghai Vitalgen BioPharma, Baxalta, Amarna therapeutics, Catalyst Biosciences, Freeline Therapeutics, Belief BioMed, Centessa Pharmaceuticals, Novo Nordisk, Sanofi, Pfizer, and others

  • Key Hemophilia B Therapies: BBM-H901, ISU304, TU7710, BE-101, REGV131, PF-06838435, ANB-002, AAV5-hFIXco-Padua, VGB-R04, AskBio009, AMA005, CB 2679d-GT, FLT180a, BBM-H901, SerpinPC, Concizumab, Fitusiran , PF-06, and others

  • Hemophilia B Therapeutic Assessment: Hemophilia B current marketed and Hemophilia B emerging therapies

  • Hemophilia B Market Dynamics: Hemophilia B market drivers and Hemophilia B market barriers

 

Get a Free Sample PDF Report to know more about Hemophilia B Pipeline Assessment

 

Table of Contents

1

Hemophilia B Report Introduction

2

Hemophilia B Executive Summary

3

Hemophilia B Overview

4

Hemophilia B- Analytical Perspective In-depth Commercial Assessment

5

Hemophilia B Pipeline Therapeutics

6

Hemophilia B Late Stage Products (Phase II/III)

7

Hemophilia B Mid Stage Products (Phase II)

8

Hemophilia B Early Stage Products (Phase I)

9

Hemophilia B Preclinical Stage Products

10

Hemophilia B Therapeutics Assessment

11

Hemophilia B Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Hemophilia B Key Companies

14

Hemophilia B Key Products

15

Hemophilia B Unmet Needs

16

Hemophilia B Market Drivers and Barriers

17

Hemophilia B Future Perspectives and Conclusion

18

Hemophilia B Analyst Views

19

Appendix

20

About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hemophilia B Pipeline 2024: Detailed Clinical Trials and FDA-Approved Therapies Review by DelveInsight | Novo Nordisk, Sanofi, Pfizer, Belief BioMed, Centessa Pharmaceuticals

Small Cell Lung Cancer Therapeutics Market Size in the 7MM is anticipated to increase by 2034 and according to DelveInsight

DelveInsight’s “Small Cell Lung Cancer Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Small Cell Lung Cancer, historical and forecasted epidemiology as well as the Small Cell Lung Cancer market trends in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan.

 

Unlock key insights into the Small Cell Lung Cancer Market! Download DelveInsight’s comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Small Cell Lung Cancer Market Size

 

Key Takeaways from the Small Cell Lung Cancer Market Report

  • In January 2025:- Hoffmann-La Roche:- The purpose of this multicenter study in China is to evaluate the safety and efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and CE in participants with untreated extensive-stage small cell lung cancer.
  • In January 2025:- AstraZeneca:- This is a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody rilvegostomig (AZD2936) is safe, tolerable and efficacious in participants with Advanced or Metastatic Non-small Cell Lung Cancer.
  • In January 2025:- Boehringer Ingelheim:- The purpose of this study is to find a suitable dose of BI 764532 that people with advanced cancer can tolerate when taken alone. 2 different doses of BI 764532 are tested in this study. Another purpose is to check whether BI 764532 can make tumours shrink. BI 764532 is an antibody-like molecule (DLL3/CD3 bispecific) that may help the immune system fight cancer.
  • It is estimated that for lung cancer in the US in 2023 are about 238,340 new cases of lung cancer (117,550 in men and 120,790 in women). The society also reported that most lung cancer statistics include both small cell lung cancer and non-small cell lung cancer. About 10% to 15% of all lung cancers are Small Cell Lung Cancer and about 80% to 85% are Non–Small Cell Lung Cancer.
  • In the United States, Small Cell Lung Cancer is slightly less common in men (13%) compared to women (14%). The risk of lung cancer increases with age. Both men and women are most likely to be diagnosed with Small Cell Lung Cancer between the ages of 75 and 79.
  • In the UK around 15 to 20 out of every 100 lung cancers (around 15 to 20%) diagnosed are this type. It is usually caused by smoking. These cancers tend to spread quite early on.
  • It has been observed that about three-quarters of Small Cell Lung Cancer patients are diagnosed with extensive-stage Small Cell Lung Cancer.
  • Among the EU4 and the UK, Germany had the highest incident population of Small Cell Lung Cancer, followed by the United Kingdom and France. On the other hand, Spain had the lowest incidence of cases of Small Cell Lung Cancer in 2022.
  • The leading Small Cell Lung Cancer Companies such as Bristol-Myers Squibb, Merck, AstraZeneca, PharmaMar, EpicentRx, and others.
  • Promising Small Cell Lung Cancer Therapies such as Atezolizumab Injection, Amivantamab, Lazertinib, Pemetrexed 500 mg, AL8326 tablets, and others.

 

Stay ahead in the competitive landscape of the Small Cell Lung Cancer Market. Access DelveInsight’s in-depth market analysis and strategic insights today! Click here for more @ Small Cell Lung Cancer Treatment Market Size

 

Small Cell Lung Cancer Epidemiology Segmentation in the 7MM

  • Total Small Cell Lung Cancer Incident cases
  • Small Cell Lung Cancer gender-specific incident cases
  • Small Cell Lung Cancer age-specific incident cases
  • Small Cell Lung Cancer Line-wise treated cases

 

Download the report to understand which factors are driving Small Cell Lung Cancer epidemiology trends @ Small Cell Lung Cancer Prevalence

 

Marketed Small Cell Lung Cancer Drugs

  • ZEPZELCA (lurbinectedin): PharmaMar and Jazz Pharmaceuticals

In June 2020, the US Food and Drug Administration granted accelerated approval to ZEPZELCA (lurbinectedin) for adult patients with metastatic Small Cell Lung Cancer with disease progression on or after platinum-based chemotherapy. ZEPZELCA, also known as PM1183, is an alkylating drug that binds guanine residues within DNA. This triggers a cascade of events that can affect the activity of DNA binding proteins, including some transcription factors, and DNA repair pathways, resulting in disruption of the cell cycle and eventual cell death. ZEPZELCA is the first new drug approved for second-line treatment since 1996. ZEPZELCA offers several benefits over the standard therapy, HYMCAMTIN, with one notable advantage being a shorter treatment window. When administering ZEPZELCA intravenously, the process lasts for a mere hour, occurring once every three weeks. Conversely, the older therapy necessitates a more time-consuming regimen, requiring a five-day intravenous course of treatment every three weeks.

 

  • IMFINZI (durvalumab): AstraZeneca

In March 2020, the US Food and Drug Administration approved IMFINZI (durvalumab), in combination with etoposide and either carboplatin or cisplatin as the first-line treatment of patients with extensive-stage Small Cell Lung Cancer. IMFINZI is a human monoclonal antibody that binds to PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80, countering the tumor’s immune-evading tactics and releasing the inhibition of immune responses.

 

Emerging Small Cell Lung Cancer Drugs

  • RRx-001: EpicentRx

RRx-001, which is being investigated by EpicentRx, is a highly selective NLRP3 inhibitor under investigation in a Phase III trial for the treatment of Small Cell Lung Cancer. Currently, the 3L+ Small Cell Lung Cancer REPLATINUM Phase III study is enrolling patients in the US and China. RRx-001, a tumor-activated small molecule that inhibits the NLRP3 inflammasome and repolarizes tumor-associated macrophages (TAMs), is used to restore sensitivity to chemotherapy that has already been tried.

 

Discover the future of Small Cell Lung Cancer Treatments with DelveInsight’s latest market report. Get expert insights and forecasts—download now! @ Small Cell Lung Cancer Market Drivers and Barriers

 

Small Cell Lung Cancer Drugs Market Landscape

Immunotherapies, including immune checkpoint inhibitors (ICIs), have revolutionized the treatment of various cancers and have emerged as a topic of immense interest in the case of Small Cell Lung Cancer (Small Cell Lung Cancer). Notably, recent advancements have shown improved survival rates in extensive-stage Small Cell Lung Cancer through the incorporation of anti-programmed death ligand 1 (PD-L1) inhibitors alongside platinum-based chemotherapy as the primary treatment. Consequently, the combination of chemoimmunotherapy has now gained official approval as the standard of care.

 

Small Cell Lung Cancer Market Outlook

For the last three decades, there has been minimal progress in enhancing the survival rates of patients afflicted with Small Cell Lung Cancer. Unfortunately, the clinical outcomes for these patients continue to be unfavorable primarily due to the disease’s rapid cell division, propensity for early and extensive metastasis, and the development of resistance to chemotherapy. There are a number of treatment options for Small Cell Lung Cancer. These treatment options are used to treat a specific patient’s lung cancer that depends on the stage of cancer, the patient’s overall health, including how well the organs of the patient’s body are functioning, and the patient’s preferences. Surgery, chemotherapy, radiation therapy, and immunotherapy are approved and mainly used treatment choices.

 

Small Cell Lung Cancer Treatment Market

The choice of treatment option is dependent on the stage of Small Cell Lung Cancer, symptoms, age, how fast it is growing, and whether patients may suffer various patterns of recurrence requiring subsequent lines of rescue therapies. The most commonly used chemotherapy regimen is Etoposide or Irinotecan plus a platinum-based drug such as Cisplatin or Carboplatin. For people with limited-stage Small Cell Lung Cancer, chemotherapy plus radiation therapy to the chest is given daily over several weeks. People with extensive-stage cancer initially receive chemotherapy for 3 to 4 months or they may receive chemotherapy in combination with immunotherapy.

 

Explore the dynamics of the Small Cell Lung Cancer Market with DelveInsight. From market size to emerging drugs—find it all in our latest report. Read now! @ Small Cell Lung Cancer Ongoing Clinical Trials Analysis

 

Scope of the Small Cell Lung Cancer Market Report

  • Coverage- 7MM
  • Study Period- 2020-2034
  • Small Cell Lung Cancer Companies- Bristol-Myers Squibb, Merck, AstraZeneca, PharmaMar, EpicentRx, and others.
  • Small Cell Lung Cancer Therapies- Atezolizumab Injection, Amivantamab, Lazertinib, Pemetrexed 500 mg, AL8326 tablets, and others.
  • Small Cell Lung Cancer Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Small Cell Lung Cancer Unmet Needs, KOL’s views, Analyst’s views, Small Cell Lung Cancer Market Access and Reimbursement

 

Table of Content

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

5. Epidemiology and Market Forecast Methodology

6. Small-cell Lung Cancer Market Overview at a Glance

7. Small Cell Lung cancer (SCLC): Disease Background and Overview

8. Small Cell Lung Cancer Epidemiology and Patient Population: 7MM

9. Current Treatment Practices for Small-cell Lung Cancer (Small-cell Lung Cancer)

10. Small Cell Lung Cancer Patient Journey

11. Key Endpoints in Small-cell Lung Cancer Clinical Trials

12. Marketed Small Cell Lung Cancer Products

List to be continued……

13. Emerging Small Cell Lung Cancer Therapies

14. Small Cell Lung cancer Market: Seven Major Market Analyses

15. Small Cell Lung Cancer Unmet Needs

16. Small Cell Lung Cancer SWOT Analysis

17. Small Cell Lung Cancer KOL Views

18. Small Cell Lung Cancer Market Access and Reimbursement Scenario

19. Appendix

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Small Cell Lung Cancer Therapeutics Market Size in the 7MM is anticipated to increase by 2034 and according to DelveInsight

Industrial Motors Market Poised for $2.92 Bn Revenue Across Southeast Asia – Sales to Reach 6.50 Million Units – Arizton

“Southeast Asia Industrial Motors Market Research Report by Arizton”

According to Arizton’s latest research report, the Southeast Asia industrial motors market is growing at a CAGR of 5.86% during 2023-2029.

 

Looking for More Information? Click:https://www.arizton.com/market-reports/southeast-asia-industrial-motors-market

 

Report Scope:          

Market Size – Revenue (2029): $2.92 Billion 

Market Size – Revenue (2023): $2.08 Billion  

CAGR – Revenue (2023-2029): 5.86% 

Market Size – Shipments (2029): 6.50 Million Units

Historic Year: 2020-2022     

Base Year: 2023       

Forecast Year: 2024-2029     

Market Segmentation: Product, Power Output, Voltage, Low Voltage AC Motor By Efficiency, Sales Channel, End Users, and Geography

Geographical Analysis: Southeast Asia (Indonesia, Thailand, Singapore, Malaysia, Vietnam, Philippines, and the Rest of Southeast Asia)

 

The industrial motors market in Southeast Asia is experiencing robust growth. Key countries like Vietnam, Thailand, and Indonesia are seeing strong industrial expansion, particularly in manufacturing and construction sectors. Large infrastructure projects, favorable trade policies, and cost-effective labor are attracting foreign investments, further boosting motor demand. The region’s adoption of advanced manufacturing technologies and automation is increasing the need for high-quality industrial motors, especially in automotive, electronics, and assembly lines. Additionally, government policies promoting energy-efficient motors, alongside the rise of Industry 4.0 and electric vehicle production, are fueling demand for intelligent, high-performance motors across various industries.

 

Market Opportunities & Trends

Adoption of IE3 and IE4 Motors to Enhance Energy Efficiency

IE3 and IE4 motors are designed to account for lower energy consumption than standard motors, resulting in substantial cost savings and a lower environmental footprint. Several Southeast Asian nations are implementing regulations and standards that promote or require the use of high-efficiency motors, emphasizing sustainability and energy conservation. Ongoing advances in motor technology are making IE3 and IE4 motors more affordable and accessible for a broad range of applications.

Rising Demand for EVs

Southeast Asia is witnessing a rise in EV demand, driven by government incentives, environmental concerns, and increased consumer awareness. This surge is fueling the need for industrial motors used in EV manufacturing. Countries such as Thailand, Indonesia, and Vietnam are implementing supportive policies, including subsidies, tax exemptions, and local production requirements, encouraging manufacturers to boost EV production, which is driving the demand for industrial motors.

 

Growth of Direct to OEM Sales Channel in Southeast Asia Industrial Motors Market

The Southeast Asia industrial motors market is seeing significant growth through the Direct to OEM (Original Equipment Manufacturer) sales channel. In this model, industrial motors are sold directly to manufacturers who incorporate them into their equipment for resale. By eliminating intermediaries, this approach offers more competitive pricing and fosters closer customer relationships.

Demand for Direct to OEM sales is growing as industries in Southeast Asia seek customized, high-performance motors for their production lines and machinery. For instance, automotive manufacturers in Thailand are increasingly sourcing motors directly for their assembly lines, while textile companies in Indonesia are purchasing motors to power weaving and spinning machinery. Similarly, the electronics market in Malaysia is experiencing growth in the demand for OEM motors for specialized manufacturing equipment.

As Southeast Asia’s manufacturing sector continues to expand, the Direct to OEM segment is projected to reach USD 1.89 billion by 2029, fueled by the region’s ongoing shift towards more efficient and integrated production processes.

 

Buy this Research @ https://www.arizton.com/market-reports/southeast-asia-industrial-motors-market

 

Key Company Profiles

  • ABB Ltd
  • Siemens AG
  • WEG S.A.
  • Mitsubishi Electric Corporation
  • TECO Electric & Machinery Co., Ltd
  • Nidec Corporation
  • Regal Rexnord Corporation
  • Hyosung Corporation
  • Toshiba Corporation
  • Fuji Electric Co., Ltd
  • Hitachi, Ltd
  • Schneider Electric SE
  • Emerson Electric Co
  • Baldor Electric Company
  • Leroy-Somer
  • SEW-Eurodrive GmbH & Co. KG
  • Oriental Motor Co., Ltd.
  • Sumitomo Heavy Industries, Ltd
  • Johnson Electric Holdings Limited
  • Hoyer Motors
  • Brook Crompton Holdings Ltd
  • Hong Ky Company Limited
  • Winston Engineering
  • Dolin M&E Technology Manufacture Co., Ltd

 

Market Segmentation

 

Product

  • AC Motor
  • DC Motor

 

Power Output

  • IHP
  • FHP

 

Voltage

  • Low
  • Medium
  • High

 

Low Voltage AC Motor by Efficiency

  • IE1
  • IE2
  • IE3
  • IE4

 

Sales Channel

  • Direct to OEM
  • Direct to End-User
  • Distributor to End-User
  • Distributor to OEM
  • Direct to System Integrator
  • Distributor To System Integrator

 

End Users

  • Mining
  • Power Generation
  • Metal Processing
  • Oil & Gas
  • HVAC
  • F&B
  • Paper & Paperboard
  • Automotive
  • Chemical
  • Packaging
  • Warehousing
  • Machine Tools
  • Elevator & Escalator
  • Pharmaceutical
  • Others

 

Geography

  • Southeast Asia
  • Indonesia
  • Thailand
  • Singapore
  • Malaysia
  • Vietnam
  • Philippines
  • The Rest of Southeast Asia

     

The Arizton Advisory & Intelligence market research report provides valuable market insights for industry stakeholders, investors, researchers, consultants, and business strategists aiming to understand the Southeast Asia industrial motors market thoroughly. Request for Free Sample to get a glance at the report now: https://www.arizton.com/market-reports/southeast-asia-industrial-motors-market

 

What Key Findings Will Our Research Analysis Reveal?        

How big is the Southeast Asia industrial motors market?

What is the growth rate of the Southeast Asia industrial motors market?

Which region dominates the Southeast Asia industrial motors market share?

What are the significant trends in the Southeast Asia industrial motors market?

Who are the key players in the Southeast Asia industrial motors market?

        

Other Related Reports that Might be of Your Business Requirement        

U.S. Electric Tractor Market – Industry Outlook & Forecast 2024-2029

https://www.arizton.com/market-reports/us-electric-tractor-market

Electric Outboard Motors Market – Global Outlook & Forecast 2024-2029

https://www.arizton.com/market-reports/electric-outboard-motors-market

 

Why Arizton?                                                   

100% Customer Satisfaction                                                   

24×7 availability – we are always there when you need us                                                   

200+ Fortune 500 Companies trust Arizton’s report                                                   

80% of our reports are exclusive and first in the industry                                                   

100% more data and analysis                                                   

1500+ reports published till date                                 

                      

Post-Purchase Benefit                                               

  • 1hr of free analyst discussion                                               
  • 10% off on customization                            

                     

About Us:                                                                                        

Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.

We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.

Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports. 

Media Contact
Company Name: Arizton Advisory & Intelligence
Contact Person: Jessica
Email: Send Email
Phone: +1 3122332770
Country: United States
Website: https://www.arizton.com/market-reports/southeast-asia-industrial-motors-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Industrial Motors Market Poised for $2.92 Bn Revenue Across Southeast Asia – Sales to Reach 6.50 Million Units – Arizton

Chronic Pulmonary Infections Pipeline 2024: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Teva Pharma, Merck, F. Hoffmann-La Roche, Novartis, GlaxoSmithKline, AstraZeneca

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Chronic Pulmonary Infections pipeline constitutes 10+ key companies continuously working towards developing 15+ Chronic Pulmonary Infections treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

“Chronic Pulmonary Infections Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Pulmonary Infections Market.

 

The Chronic Pulmonary Infections Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Chronic Pulmonary Infections Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Chronic Pulmonary Infections treatment therapies with a considerable amount of success over the years.

  • Chronic Pulmonary Infections companies working in the treatment market are Armata Pharmaceuticals, BiomX, Inc., Respirion Pharmaceuticals, Chiesi Farmaceutici S.p.A., Incyte Corporation, American Health Research, Temple University, Altesa Biosciences, Genentech, Inc., and others, are developing therapies for the Chronic Pulmonary Infections treatment

  • Emerging Chronic Pulmonary Infections therapies in the different phases of clinical trials are- AP-PA02, BX004-A, RSP-1502, CHF6001, itacitinib, Guafenesin tablets, Quercetin, Vapendavir, GDC-6599, and others are expected to have a significant impact on the Chronic Pulmonary Infections market in the coming years.

  • In December 2024, Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a biotechnology company dedicated to developing high-purity, pathogen-specific bacteriophage therapies for chronic pulmonary diseases and antibiotic-resistant bacterial infections, has announced promising topline results from its Phase 2 “Tailwind” trial. The trial assessed the efficacy of AP-PA02, an innovative inhaled multi-phage therapeutic designed to treat chronic pulmonary Pseudomonas aeruginosa (P. aeruginosa) infections in patients with non-cystic fibrosis bronchiectasis (NCFB).

  • In May 2024, Insmed’s stock price surged over 100% following the announcement that their leading pipeline candidate, brensocatib, achieved success in a Phase III trial. The much-anticipated ASPEN trial (NCT04594369) was an international, randomized, double-blind, placebo-controlled Phase III study designed to evaluate the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis.

  • In May 2024, Pfizer Inc. (NYSE: PFE) has released extended follow-up results from the Phase 3 CROWN trial, which compared LORBRENA® (lorlatinib), a third-generation ALK inhibitor, to XALKORI® (crizotinib) in patients with previously untreated, ALK-positive advanced non-small cell lung cancer (NSCLC). After a median follow-up of five years, the median progression-free survival (PFS) for LORBRENA, as assessed by investigators, was not reached. The observed Hazard Ratio (HR) was 0.19 (95% Confidence Interval [CI], 0.13-0.27), indicating an 81% reduction in disease progression or death compared to XALKORI.

 

Chronic Pulmonary Infections Overview

Chronic pulmonary infections refer to persistent or long-lasting infections affecting the respiratory system, particularly the lungs. These infections can be caused by various pathogens such as bacteria, viruses, fungi, or parasites. Chronic pulmonary infections are characterized by their prolonged duration and can lead to significant respiratory symptoms and complications if not properly managed.

 

Get a Free Sample PDF Report to know more about Chronic Pulmonary Infections Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/chronic-pulmonary-infections-pipeline-insight

 

Emerging Chronic Pulmonary Infections Drugs Under Different Phases of Clinical Development Include:

  • AP-PA02: Armata Pharmaceuticals

  • BX004-A: BiomX, Inc.

  • RSP-1502: Respirion Pharmaceuticals

  • CHF6001: Chiesi Farmaceutici S.p.A.

  • itacitinib: Incyte Corporation

  • Guafenesin tablets: American Health Research

  • Quercetin: Temple University

  • Vapendavir: Altesa Biosciences

  • GDC-6599: Genentech, Inc.

 

Chronic Pulmonary Infections Route of Administration

Chronic Pulmonary Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Intravenous

  • Subcutaneous

  • Oral

  • Intramuscular

 

Chronic Pulmonary Infections Molecule Type

Chronic Pulmonary Infections Products have been categorized under various Molecule types, such as

  • Monoclonal antibody

  • Small molecule

  • Peptide

 

Chronic Pulmonary Infections Pipeline Therapeutics Assessment

  • Chronic Pulmonary Infections Assessment by Product Type

  • Chronic Pulmonary Infections By Stage and Product Type

  • Chronic Pulmonary Infections Assessment by Route of Administration

  • Chronic Pulmonary Infections By Stage and Route of Administration

  • Chronic Pulmonary Infections Assessment by Molecule Type

  • Chronic Pulmonary Infections by Stage and Molecule Type

 

DelveInsight’s Chronic Pulmonary Infections Report covers around 15+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Chronic Pulmonary Infections product details are provided in the report. Download the Chronic Pulmonary Infections pipeline report to learn more about the emerging Chronic Pulmonary Infections therapies

 

Some of the key companies in the Chronic Pulmonary Infections Therapeutics Market include:

Key companies developing therapies for Chronic Pulmonary Infections are – Merck & Co., Inc., F. Hoffmann-La Roche Ltd, Novartis AG, GlaxoSmithKline Plc, AstraZeneca Plc, Boehringer Ingelheim International Gmbh, Teva Pharmaceutical Industries Ltd, Sanofi, Mylan Pharmaceuticals, Sun Pharmaceutical, and others.

 

Chronic Pulmonary Infections Pipeline Analysis:

The Chronic Pulmonary Infections pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Pulmonary Infections with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Pulmonary Infections Treatment.

  • Chronic Pulmonary Infections key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Chronic Pulmonary Infections Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Pulmonary Infections market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Chronic Pulmonary Infections drugs and therapies

 

Chronic Pulmonary Infections Pipeline Market Drivers

  • Increasing Prevalence, Unmet Medical Needs, Advancements in Biotechnology, Government Initiatives, Growing Healthcare Expenditure, are some of the important factors that are fueling the Chronic Pulmonary Infections Market.

 

Chronic Pulmonary Infections Pipeline Market Barriers

  • However, Complexity in Diagnosis, Regulatory Hurdles, High Development Costs, Antibiotic Resistance, Limited Awareness, and other factors are creating obstacles in the Chronic Pulmonary Infections Market growth.

 

Scope of Chronic Pulmonary Infections Pipeline Drug Insight

  • Coverage: Global

  • Key Chronic Pulmonary Infections Companies: Armata Pharmaceuticals, BiomX, Inc., Respirion Pharmaceuticals, Chiesi Farmaceutici S.p.A., Incyte Corporation, American Health Research, Temple University, Altesa Biosciences, Genentech, Inc., and others

  • Key Chronic Pulmonary Infections Therapies: AP-PA02, BX004-A, RSP-1502, CHF6001, itacitinib, Guafenesin tablets, Quercetin, Vapendavir, GDC-6599, and others

  • Chronic Pulmonary Infections Therapeutic Assessment: Chronic Pulmonary Infections current marketed and Chronic Pulmonary Infections emerging therapies

  • Chronic Pulmonary Infections Market Dynamics: Chronic Pulmonary Infections market drivers and Chronic Pulmonary Infections market barriers

 

Request for Sample PDF Report for Chronic Pulmonary Infections Pipeline Assessment and clinical trials

 

Table of Contents

1. Chronic Pulmonary Infections Report Introduction

2. Chronic Pulmonary Infections Executive Summary

3. Chronic Pulmonary Infections Overview

4. Chronic Pulmonary Infections- Analytical Perspective In-depth Commercial Assessment

5. Chronic Pulmonary Infections Pipeline Therapeutics

6. Chronic Pulmonary Infections Late Stage Products (Phase II/III)

7. Chronic Pulmonary Infections Mid Stage Products (Phase II)

8. Chronic Pulmonary Infections Early Stage Products (Phase I)

9. Chronic Pulmonary Infections Preclinical Stage Products

10. Chronic Pulmonary Infections Therapeutics Assessment

11. Chronic Pulmonary Infections Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Chronic Pulmonary Infections Key Companies

14. Chronic Pulmonary Infections Key Products

15. Chronic Pulmonary Infections Unmet Needs

16 . Chronic Pulmonary Infections Market Drivers and Barriers

17. Chronic Pulmonary Infections Future Perspectives and Conclusion

18. Chronic Pulmonary Infections Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Pulmonary Infections Pipeline 2024: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Teva Pharma, Merck, F. Hoffmann-La Roche, Novartis, GlaxoSmithKline, AstraZeneca

Polymer Foam Market: An Analysis of Size, Shares, Business Growth, and Upcoming Trends Forecast 2024-2030

“Browse 233 market data Tables and 50 Figures spread through 287 Pages and in-depth TOC on “Polymer Foam Market””
Polymer foam plays a vital role across industries due to its lightweight, insulation, and cushioning properties. Growing demand in packaging, construction, and automotive sectors drives market expansion. Innovations in eco-friendly and biodegradable foams further enhance its growth prospects.

The global polymer foam market is projected to grow from USD 102.61 billion in 2024 to USD 142.02 billion by 2030, at a CAGR of 5.6% during the forecast period. One of the most important drivers for this polymer foam market has been the growth in global construction activities, particularly in emerging economies. Demand for polymer foams in residential and commercial construction is growing, with room for more materials that would bring in thermal insulation, soundproofing, and energy efficiency to buildings. The building industry widely employs polymer foams such as PU, EPS, and polyolefin because of their lightweight properties, insulation from heat, and relatively easy installation. In the building sector, polymer foams are used in flooring, insulation panels in walls, and roofing applications. These account for energy conservation by maintaining the temperature inside the house.

The building & construction segment is expected to account for the largest share of the polymer foam market by end-use industry during the forecast period in terms of value.

By end-use industry, the building & construction segment is estimated to have the largest market share by value. Due to the rising need for energy-efficient and environmentally friendly construction materials, the building and construction industry will continue dominating the polymer foams market. Various polymer foams including, but not limited to, polyurethane (PU) and polystyrene (PS), find applications in thermal and acoustical insulation as well as structural infill systems within walls, roofs, and flooring, thereby contributing to the building’s energy performance. In addition to these factors, concerns about green building practices and energy efficiency and associated government policies encouraging low-energy buildings have increased the use of polymer foams in the scope of both residential and commercial construction. Moreover, polymer foams have the advantage of being light in weight, hence less conducive to higher construction costs and enhancing the ability of the buildings to withstand better.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1011

By resin type, the polyurethane segment is expected to account for the largest market share in terms of value during the forecast period.

Based on resin type, the polyurethane segment is estimated to account for the largest share of the market during the forecast period. This unique market share can be attributed to polyurethane’s versatility and a vast range of applications in major sectors, including automotive, construction, packaging, and bedding and furniture sectors. Both rigid and flexible polyurethane foams are often chosen due to characteristics like durability and lightweight nature. Polyurethane is used for soundproofing, energy absorption, and thermal insulation applications in the building and construction industry. It is also found in the automotive sector and in sealing and cushioning functions. Thus, polyurethane’s ability to meet a wide range of functional requirements is one of the primary reasons for its dominance in the polymer foam market.

Asia Pacific is projected to register the largest market share during the forecast period.

Asia Pacific is estimated to lead the market during the forecast period. The Asia-Pacific region is expected to have the largest market share in the polymer foam market due to numerous factors. The rapid urbanization and industrialization of countries and areas in the Asia Pacific have led to a substantial increase in demand for polymer foams in construction industries, automotive, and packaging, especially in developing countries such as China, India, and Southeast Asian countries. The increasing construction activities in these regions utilize polymer foams in residential and commercial buildings for insulation, soundproofing, and structural uses. Also boosting the product demand is the region’s growing automotive manufacturing sector, which is on the rise due to lightweight materials, such as polyurethane and polystyrene foams, which help improve the efficiency of motor vehicles. Due to the expansion of the e-commerce and retail industries in the Asia Pacific region, there has also been an increasing requirement for polymer foams used in packaging. In addition, the growth of this market is facilitated by the presence of cheap raw materials and labor and the growing commitment towards investments in eco-friendly foam technologies.

Polymer Foam Companies

Companies such as ARMACELL (Luxembourg), Sheela Foam Limited (India), Kingspan Insulation, LLC (Ireland), Owens Corning (US), and Zotefoams plc (UK) fall under the winners’ category. These are leading players in the Polymer foam market globally. These players have adopted the strategies of acquisitions, expansions, partnerships, and product launches to increase their market shares.

ARMACELL

ARMACELL produces and distributes advanced insulation and engineered foams for the equipment insulation market. The company is one of the major solution providers for flexible technical (mechanical) insulation materials and products based on foam technologies. It offers numerous products, including insulation materials, fire protection products, acoustic solutions & covering systems for building equipment and industrial installations, foam cores as composite materials, and special foams for various industrial applications.

Request PDF Sample Copy: https://www.marketsandmarkets.com/requestsampleNew.asp?id=1011

The company operates in two business segments: Advanced Insulation and Engineered Foams. The Advanced Insulation segment tackles equipment protection and optimization with innovative, flexible foam solutions. Their focus lies on ensuring technical equipment stays well-insulated and protected. It co-designs energy-efficient systems for commercial, industrial, energy, and transportation industries to identify areas for energy savings and then design systems to achieve those goals.

Sheela Foam Limited

Sheela Foam Limited has carved a niche as the frontrunner in India’s polyurethane (PU) foam industry. Their manufacturing footprint spans the entire nation, solidifying their position as a domestic leader. However, their vision stretches beyond borders as they possess a global marketing perspective, aiming to leave their mark on the international stage. Over the past five decades, Sheela Foam Limited has built an unwavering reputation for excellence. Their commitment to quality and innovation has resulted in an impeccable track record, earning customers’ trust nationwide. The company operates through four business segments: mattress, technical foam, furniture foam, comfort foam, and homecare products.

Sheela Foam Limited’s success is further solidified by its winning portfolio of brands. SLEEPWELL, their flagship brand, is at the forefront and synonymous with mattresses and comfort accessories. It is a household name trusted by many for a good night’s sleep and overall well-being.

Kingspan Insulation, LLC

Kingspan Insulation, LLC is a subsidiary of Kingspan Group plc, a leading insulation solutions provider for residential and non-residential applications. It operates five business segments: Insulated Panels; Insulation; Roofing & Waterproofing; Light, Air & Water; and Data & Flooring. It has more than 22,000 employees worldwide and 212 manufacturing sites globally. The insulation boards segment offers industrial insulation materials, such as mineral wool and foam, to the power, petrochemical, and food & beverage industries. The company shapes the future of sustainable building.

Kingspan understands the link between sustainable construction and human health. It ensures that its building solutions promote healthy and comfortable living spaces. Its commitment to ethical practices and research into new technologies to reduce environmental impact keeps it at the forefront of sustainable construction.

Kingspan’s commitment extends beyond individual buildings; it advocates for broader industry-wide changes that promote sustainable construction practices. Through collaboration and innovation, Kingspan is shaping a future where sustainable building is not just the exception but the norm.

Inquire Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=1011

Owens Corning

Owens Corning is a global fiberglass manufacturing company that offers high-, mid-, and low-temperature thermal and acoustic products. The company operates through the Roofing, Insulation, and Composites segments. It provides insulation solutions to commercial, industrial, and residential sectors. Owens Corning operates in 33 countries and sells its insulation products to the US, Canada, Europe, Asia Pacific, and Latin America. It has OEM manufacturing facilities in the US, Mexico, and China and OEM fabrication facilities in the US, Mexico, Italy, and Poland.

Zotefoams plc

Zotefoams plc is one of the leading manufacturers of closed-cell cross-linked polyolefin foams for use in sports, construction, marine, automation, medical equipment, and aerospace industries. The company has two manufacturing plants, one in Croydon, UK, and the other in Kentucky, US. It also has a joint venture to distribute its AZOTE foams in Asia.

The company has a worldwide network of regulated distributors who sell Zotefoams products. It also set up a joint venture in Nagoya, Japan, to cover the block foam market in Asia and the Kunshan ZOTEK KingLai business in China to develop the T-FIT insulation system. It operates under three business segments: Polyolefin Foams, High-performance Products (HPP), and MuCell Extrusion, LLC (MEL).

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/foams-market-1011.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Polymer Foam Market: An Analysis of Size, Shares, Business Growth, and Upcoming Trends Forecast 2024-2030

Sorgho Squad Entertainment to Highlight Environmental Sustainability at Sundance

“Photo credit: Jeff Lewis Photography”
Sorghum United will present “Creating a Pathway to Environmental Sustainability, Global Affordability, and Environmental Food Security Through Entertainment” at the Sundance Film Festival, showcasing how their Sorgho Squad initiative combines engaging storytelling with sustainable solutions to promote the benefits of sorghum and millets worldwide.

Sorghum United, a global nonprofit dedicated to raising awareness on the benefits and uses of sorghum and millet, is excited to announce a presentation at the Sundance Film Festival on Tuesday, January 28th, from 11:30-12:30 p.m. The session, titled “Creating a Pathway to Environmental Sustainability, Global Affordability, and Environmental Food Security Through Entertainment,” will be led by Nate Blum, CEO of Sorghum United.

During the hour-long presentation, Blum will provide insights into how the Sorgho Squad entertainment, featuring books, a video game, and an upcoming TV show, addresses global environmental challenges, all aimed at engaging diverse audiences in meaningful conversations about sustainability.

Sorgho Squad is an educational initiative by Sorghum United that uses adventure stories to promote the benefits of sorghum and millet. The series features a team of characters, including Professor Sorgho and his assistant Alice Atlas on their quest to rediscover an ancient grain super-team known as the Sorgho Squad. Sorghum United’s mission to support and empower the entire sorghum and millet value chain is at the heart of the Sorgho Squad initiative.

Blum’s presentation will highlight the unique narratives and characters of Sorgho Squad, demonstrating how their mission and narrative provide both entertainment and valuable lessons on sustainable practices and food security. The Sundance attendees will also gain insights into the creative process behind Sorgho Squad entertainment and how it seeks to inspire a global audience to take action on critical environmental issues, along with an opportunity to see how these innovative efforts are shaping the future for sustainable food production with a little additive of entertainment and Hollywood razzle dazzle. Sorghum United and Sorgho Squad have also recently teamed up with the Real Housewives of Orange County and New Jersey for a promo video. Sorgho Squad will be seen around Oscars week, as they are participating in a celebrity gifting suite on 2/27.

About Sorghum United

Sorghum United is a global nonprofit organization committed to empowering all levels of the sorghum and millet value chains. Through innovative initiatives like Sorgho Squad Entertainment, they strive to enhance regional food security, improve nutritional outcomes, and promote climate sustainability. Sorghum United works with farmers, consumers, and industry leaders to create a more sustainable and nutritious future.

For more information, please visit www.sorghumunited.com and www.sorghosquad.com.

Media Contact
Company Name: At Large PR
Contact Person: Jeff Bearden
Email: Send Email
Country: United States
Website: www.atlargepr.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Sorgho Squad Entertainment to Highlight Environmental Sustainability at Sundance

BMR Belmax Remodeling Brings Services to Newtown, PA with Seasonal Offers

Newtown, PA – Jan 27, 2025 – Homeowners in Newtown, PA, now have a trusted partner for all their remodeling needs. BMR Belmax Remodeling, known for exceptional craftsmanship and personalized designs, is expanding its services to the Newtown community. To celebrate this milestone, the company is offering exclusive seasonal discounts on select remodeling services, making it the perfect time for homeowners to enhance their living spaces.

With years of experience delivering high-quality renovations, BMR Belmax Remodeling specializes in creating beautiful, functional homes. Their comprehensive services include kitchen remodeling, bathroom renovations, basement finishing, and home additions, all designed to meet the unique needs and styles of their clients. Now, residents of Newtown can experience the same exceptional quality and customer-focused approach that has made BMR Belmax Remodeling a trusted name in home improvement.

Seasonal Offers for Newtown Residents

To mark its expansion, BMR Belmax Remodeling is providing limited-time seasonal offers on its most popular services:

  • Kitchen Remodeling: Transform your kitchen into a modern, elegant space with custom cabinetry, energy-efficient appliances, and premium finishes.
  • Bathroom Renovations: Create a luxurious, spa-inspired retreat with updated fixtures, sleek tiling, and tailored layouts.
  • Basement Finishing: Maximize your home’s potential by turning your basement into a functional and stylish living area, perfect for entertaining, working, or relaxing.
  • Home Additions: Seamlessly expand your living space with well-designed additions that blend perfectly with your home’s architecture.

These discounts provide Newtown homeowners with an excellent opportunity to start their remodeling projects at an affordable cost while still enjoying the high standards of craftsmanship that BMR Belmax Remodeling is known for.

Commitment to Excellence

“Our expansion to Newtown, PA, is a significant step in our mission to provide exceptional remodeling services to more homeowners,” said [Your Name/CEO of BMR Belmax Remodeling]. “We’re thrilled to become a part of this vibrant community, and we’re excited to offer special seasonal discounts to help Newtown residents bring their dream spaces to life. At BMR Belmax Remodeling, we take pride in our ability to turn visions into reality with unmatched craftsmanship and customer service.”

Why Choose BMR Belmax Remodeling?

Homeowners across Pennsylvania trust BMR Belmax Remodeling for their home improvement projects due to the company’s unwavering dedication to:

  • Custom Designs: Tailored solutions that meet the individual style and functionality needs of each client.
  • Exceptional Craftsmanship: High-quality materials and expert workmanship for results that last.
  • Customer Satisfaction: Transparent communication and a focus on delivering projects on time and within budget.

About BMR Belmax Remodeling

BMR Belmax Remodeling specializes in comprehensive home remodeling services, including kitchens, bathrooms, basements, and full-home renovations. With a reputation for excellence and innovation, the company is committed to helping homeowners enhance the beauty, comfort, and value of their homes.

Take Advantage of Seasonal Discounts

Newtown homeowners are encouraged to act quickly and take advantage of these exclusive seasonal offers. Contact BMR Belmax Remodeling today to schedule a consultation and start your home transformation with expert craftsmanship and tailored designs.

Media Contact
Company Name: BMR Belmax Remodeling
Email: Send Email
Phone: +1 609-712-27-50
Address:1008 Barry Court
City: Southampton
State: PA 18966
Country: United States
Website: https://belmaxremodeling.com/areas-we-serve/newtown-pa/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: BMR Belmax Remodeling Brings Services to Newtown, PA with Seasonal Offers

The CCTV4 “Festival of Spring 2025” Gala A Global Celebration for Chinese People Everywhere

Spring Festival this year will be the first since the traditional celebrations were listed as part of the Intangible Cultural Heritage of Humanity. China Media Group will mark the occasion – the start of the Year of the Snake – with a special gala highlighting the holiday’s growing influence around the world.

“Festival of Spring 2025: A Worldwide Celebration of Chinese New Year” will comprise three chapters: “A Shared Spring”, “Spirit of the Overseas Chinese” and “Greetings for the New Year”. As part of the rich and varied program there will be songs and dances reflecting the sense of missing home felt by Chinese people, old and young, living overseas, and their memories of past Spring Festivals.

Among the performers will be famous artists Tsai Chin and Chiang Yu-Heng. Also appearing will be representatives of the Chinese communities in the US, Australia and Russia, as well as foreign guests who will describe the New Year celebrations in their own countries. Short video creator Li Ziqi will highlight the traditional aspects of the holiday and share her unique insights into the work of preserving China’s intangible cultural heritage.

Once celebrated mainly just in China, Spring Festival is now a major holiday for people across the globe. “Festival of Spring 2025: A Worldwide Celebration of the Chinese New Year” will be broadcast at 7:30 pm (Beijing Time) on January 29 on CCTV 4.

Media Contact
Company Name: Festival of Spring
Contact Person: Zhang Ping
Email: Send Email
Country: China
Website: https://www.youtube.com/@CCTVCH

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The CCTV4 “Festival of Spring 2025” Gala A Global Celebration for Chinese People Everywhere

Evolving Trends in Southeast Asia’s F&B Industry: A Focus on Health, Convenience, and Sustainability

A growing trend towards health-conscious eating is emerging in Southeast Asia, driven by an increased awareness of nutrition and a commitment for personal wellness.

With the increase in health-conscious consumers in the region, the health and wellness food market in Asia-Pacific is projected to grow at a compound annual growth rate (CAGR) of 9.9% by 2029. As urban lifestyles become busier, more people in Southeast Asia are seeking quick yet nutritious food options that enhance their personal well-being.

The rise of modern, health-conscious food habits in Southeast Asia

The rising demand for organic, whole, and plant-based foods in the region indicates a significant shift in consumer preferences. Global health trends and social media have played a significant role, spreading awareness of nutrition while enhancing appreciation for local diets rooted in natural ingredients. Furthermore, access to technology has empowered Southeast Asians to learn about healthy eating habits, often utilizing digital resources such as apps, blogs, and health websites. As knowledge of nutrition improves, consumers are becoming more conscious of the nutritional content of their food, and many are opting for choices that promise long-term health benefits.

Functional foods and superfoods continue to gain popularity in the region, with more than one-third of consumers choosing functional foods as part of their healthy eating strategy. Ingredients like turmeric, ginger, and coconut oil—known for their health benefits—are now valued for their medicinal and preventive qualities. Similarly, superfoods such as chia seeds, spirulina, and moringa have become widely available, often promoted for their nutrient density and ability to support overall wellness. Consumers are increasingly embracing these foods as a means to enrich their diets with natural nutrients, antioxidants, and anti-inflammatory properties, contributing to a holistic approach to health.

Incorporating local ingredients into diets is another important factor in this shift toward healthier eating. By choosing locally sourced produce, Southeast Asian consumers can enjoy fresher, more nutrient-dense meals while also supporting local economies. Traditional herbs and spices—like lemongrass, pandan, and kaffir lime—are becoming staples not only locally but are also recognized globally for their health-promoting properties. Choosing local produce promotes a healthier diet and offers significant ecological benefits by reducing the carbon footprint associated with imported food.

In addition to health, convenience has become a central aspect of the way Southeast Asians approach food, aligning with busy lifestyles without compromising on quality or nutrition.

The popularity of ready-to-eat meals and meal prep services has skyrocketed, especially in urban areas. These services cater to the health-conscious consumers by providing meals that are both convenient and nutritious. Companies such as Grain in Singapore and FitMeal in Thailand offer balanced, pre-portioned meals that prioritize whole ingredients. Through these services, consumers can easily access fresh and healthy meals with minimal effort, allowing them to balance wellness and convenience effortlessly.

Technology also plays a key role in promoting healthy eating. Apps and digital platforms that track nutrition, provide recipe ideas, and offer delivery services have become indispensable tools for health-conscious individuals. Delivery platforms like GrabFood and GoFood facilitate access to nutritious meals, often promoting options from health-focused eateries. Many startups in Southeast Asia leverage technology to offer convenient, health-oriented solutions, making nutritious food choices more accessible than ever.

For individuals who enjoy cooking at home, quick and easy recipes have become essential. Busy professionals are embracing simple recipes that incorporate traditional Southeast Asian flavors while maximizing nutrition. By using staple ingredients like fresh vegetables, lean proteins, and spices, individuals can prepare wholesome meals without spending hours in the kitchen. This approach allows them to enjoy healthy, home-cooked meals that align with their fast-paced lives.

An essential part of conscious eating in Southeast Asia is the emphasis on sustainability and ethical practices.

Many people in Southeast Asia are becoming aware that their food choices affect the environment. From reducing food waste to choosing plant-based meals, individuals are adopting eating habits that contribute to a more sustainable future. This shift towards plant-based diets not only benefits personal health but also reduces the carbon footprint associated with meat production. With Southeast Asia’s rich variety of plant-based ingredients, individuals can make choices that are both eco-friendly and nutritionally satisfying.

There is a growing emphasis on ethical sourcing and fair trade is also growing. Consumers are increasingly interested about the origins of their food and how it is produced. The rise of fair trade products, along with efforts by local farmers to adopt sustainable practices, have encouraged a culture of ethical consumption. By choosing products from responsible sources, Southeast Asians support fair wages for producers and promote environmentally conscious farming practices.

Community-Supported Agriculture (CSA) is a model that has gained traction in Southeast Asia, especially among those who wish to support local farmers directly. CSA initiatives allow consumers to purchase fresh, seasonal produce while fostering community connections. By participating in CSA programs, individuals can access quality produce while reducing food miles, thus contributing to local food security.

Challenges of sustainability in consumption

Despite the promising trends, there are challenges in balancing health, convenience, and sustainability.

For the Southeast Asian population, finding a balance between health, convenience, and sustainability can be challenging. However, by making informed choices and seeking products that align with these goals, consumers can enjoy both healthful and sustainable diets. Understanding product labels, choosing seasonal produce, and supporting eco-friendly brands are some ways to strike this balance.

Many people believe that healthy and sustainable eating is expensive. However, there are effective strategies to eat well on a budget, such as buying in bulk, choosing local produce, and reducing food waste. Additionally, a simple meal planning and focusing on nutrient-dense foods can make a healthy diet affordable and accessible to a wider range of consumers.

Promoting health-conscious, convenient, and sustainable eating requires a strong emphasis on education. Community initiatives and awareness programs are essential in helping consumers make informed choices. By participating in workshops, cooking classes, and online resources, individuals can learn how to make better food choices that benefit both personal health and the planet.

Southeast Asia and the future of conscious eating

Parts of the Southeast Asia region are embracing conscious eating as a way to improve health, convenience, and sustainability. By choosing healthier foods, supporting local produce, and adopting convenient eating solutions, consumers are transforming their diets to fit both personal and ecological values. As Southeast Asia continues to advance, small, manageable steps toward conscious eating can make a significant difference. Looking ahead, it’s likely that the region will see even greater innovation in food trends, with a continued focus on balancing health, convenience, and sustainability for a better, healthier future.

Who is Thanit Apipatana:

Thanit Apipatana is a Bangkok-based entrepreneur, investor, and startup advisor with a keen interest in venture building, real estate, F&B, sports and philanthropy. Mr. Apipatana has advised and invested in companies in the region, including Singapore-based proptech startup Mogul.sg and Thai-based Life Below Labs. As a thought leader, Mr. Apipatana shares his insights on entrepreneurship, F&B, education, sports and the social sector.

Media Contact
Company Name: ASEAN
Contact Person: Mathew
Email: Send Email
City: Bangkok
Country: Thailand
Website: https://www.techinasia.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Evolving Trends in Southeast Asia’s F&B Industry: A Focus on Health, Convenience, and Sustainability